Jun. 4, 2023

Roginolisib: The First Clinical Non-Competitive PI3Kd Inhibitor

IOA-244 (roginolisib)

oral QD non-competitive PI3Kd inhibitor Ph. I in metastatic cancers from focused kinase inhibitor screen (60K cmpds) + opt. Cancer Res. Commun., April 14, 2023 Merck Serono / iOnctura, CH

Drug Hunter Team

IOA-244, PI3Kd, oral QD non-competitive PI3Kd inhibitor, Ph. I in metastatic cancers, from focused kinase inhibitor screen (60K cmpds) + opt., Cancer Res. Commun., April 14, 2023 MERCK SERONO / IONCTURA, CH|||

Roginolisib: The First Clinical Non-Competitive PI3Kd Inhibitor

IOA-244 (roginolisib)

Other molecules you may be interested in